항정신병약물 임상의 역사와 미래 = History and Future of Antipsychotic Drugs

다국어 초록 (Multilingual Abstract)

After the discovery of antipsychotic drugs, the nature of clinical practice entered a period of inexorable transition. The advances of psychopharmacotherapy have interacted in complex ways with clinical practice, and the economics and policy of mental health care systems. The study of the mechanisms of action of these drugs has guided the development of hopefully improved treatment, and stimulated biological research on the pathophysiology of severe mental disorders. Despite the considerable effort to modify and change existing antipsychotic drugs, progress has been modest. This review describes the history of antipsychotic drugs and their impact on clinical practice and the study of psychiatric disorders, and offer prospects for future developments. Although finding new knowledge and methodologies to bring innovative discovery is imperative, as of now, it is important to provide comprehensive care, including the optimal use of existing antipsychotic drugs.

참고문헌 (Reference)

1 King C, "What’s in a name? The evolution of the nomenclature of antipsychotic drugs" 27 : 168-175, 2002

2 Miller R, "Validating concepts of mental disorder : precedents from the history of science" 108 : 689-699, 2014

3 Blashfield RK, "Toward a taxonomy of psychopathology : the purpose of psychiatric classification" 129 : 574-583, 1976

4 Mailman RB, "Third generation antipsychotic drugs : partial agonism or receptor functional selectivity" 16 : 488-501, 2010

5 van Rossum JM, "The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs" 160 : 492-494, 1966

6 Esterberg ML, "The psychosis continuum and categorical versus dimensional diagnostic approaches" 11 : 179-184, 2009

7 Lehmann HE, "The history of the psychopharmacology of schizophrenia" 42 : 152-162, 1997

8 Crilly J, "The history of clozapine and its emergence in the US market : a review and analysis" 18 : 39-60, 2007

9 Carpenter WT Jr, "The heterogeneity of the long-term course of schizophrenia" 14 : 645-652, 1988

10 Granger B, "The haloperidol story" 17 : 137-140, 2005

11 DeGrandpre R, "The cult of pharmacology: how America became the world’s most troubled drug culture" Duke University Press 2006

12 민성길, "The Past, Present, and Future of sychopharmacology in Korea" 대한정신약물학회 4 (4): 11-23, 2006

13 Haase HJ, "The Action of Neuroleptic Drugs: a Psychiatric, Neurologic and Pharmachological Investigation" Yearbook Medical Publishers 1965

14 Macaluso M, "Tardive dyskinesia : a historical perspective" 23 : 121-129, 2017

15 Robison RA, "Surgery of the mind, mood, and conscious state : an idea in evolution" 80 : S2-S26, 2013

16 Luigjes J, "Surgery for psychiatric disorders" 80 : S31.e17-S31.e28, 2013

17 Divry P, "Study & clinical trial of R 1625 or haloperidol, a new neuroleptic & so-called neurodysleptic agent" 59 : 337-366, 1959

18 Kirkby KC, "Social context and health consequences of the antipsychotics introduction" 17 : 141-146, 2005

19 Oyebode F, "Sims’ Symptoms in the mind: an introduction to descriptive psychopathology" Saunders Elsevier 2015

20 Insel T, "Research domain criteria(RDoC) : toward a new classification framework for research on mental disorders" 167 : 748-751, 2010

21 Divry P, "Report on the neuropsycho-pharmacological activity of haloperidol (R 1625)" 60 : 7-19, 1960

22 Frances A, "Psychopharmacology the fourth generation of progress" Raven Press, Ltd 823-, 1995

23 Dean CE, "Psychopharmacology : a house divided" 35 : 1-10, 2011

24 Mapp Y, "Psychopharmacology : II tranquilizers and antipsychotic drugs" 3 : 458-463, 1962

25 Taylor MA, "Psychopathology in neuropsychiatry : DSM and beyond" 17 : 246-249, 2005

26 Bracken P, "Psychiatry beyond the current paradigm" 201 : 430-434, 2012

27 Guttmacher MS, "Phenothiazine treatment in acute schizophrenia; effectiveness : The National Institute of Mental Health, Psychopharmacology Service Center, Collaborative Study Group" 10 : 246-261, 1964

28 Janssen PA, "Pharmacology of risperidone(R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties" 244 : 685-693, 1988

29 Miyamoto S, "Pharmacological treatment of schizophrenia : a critical review of the pharmacology and clinical effects of current and future therapeutic agents" 17 : 1206-1227, 2012

30 Schonecker M, "Paroxysmal dyskinesia as the effect of megaphen" 28 : 550-553, 1957

31 Davis JM, "Overview: maintenance therapy in psychiatry: I. Schizophrenia" 132 : 1237-1245, 1975

32 Carton L, "Off-label prescribing of antipsychotics in adults, children and elderly individuals : a systematic review of recent prescription trends" 21 : 3280-3297, 2015

33 Keshavan MS, "New drug developments in psychosis : challenges, opportunities and strategies" 152 : 3-20, 2017

34 Delay J, "Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry" 168 : 318-326, 1955

35 Shepherd M, "Neurolepsis and the psychopharmacological revolution : myth and reality" 5 : 89-96, 1994

36 Cadinu D, "NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update" 142 : 41-62, 2018

37 Kondej M, "Multi-target approach for drug discovery against schizophrenia" 19 : E3105-, 2018

38 Eisenberg L, "Mindlessness and brainlessness in psychiatry" 148 : 497-508, 1986

39 Ahonen M, "Mental Disorders in Ancient Philosophy" Spinger International Publishing 28-29, 2014

40 González Monclús E, "Medio Siglo de Psiquiatría en España" ELA 81-83, 1992

41 Roth BL, "Magic shotguns versus magic bullets : selectively non-selective drugs for mood disorders and schizophrenia" 3 : 353-359, 2004

42 Moncrieff J, "Magic bullets for mental disorders : the emergence of the concept of an"antipsychotic"drug" 22 : 30-46, 2013

43 Kumar B, "Lumateperone: a new treatment approach for neuropsychiatric disorders" 54 : 713-719, 2018

44 Wikipedia, "List of off-label promotion pharmaceutical settlements" Wikimedia Foundation

45 Divry P, "Le R1625, nouvelle thérapeutique symptomatique de l’agitation psychomotrice" 58 : 878-888, 1958

46 van Praag HM, "Kraepelin, biological psychiatry, and beyond" 258 (258): 29-32, 2008

47 López-Muñoz F, "History of the discovery and clinical introduction of chlorpromazine" 17 : 113-135, 2005

48 Kunz E, "Henri Laborit and the inhibition of action" 16 : 113-117, 2014

49 Dauvermann MR, "Glutamatergic regulation of cognition and functional brain connectivity : insights from pharmacological, genetic and translational schizophrenia research" 174 : 3136-3160, 2017

50 Jaspers K, "General Psychopathology" Manchester University Press 1963

51 Deniker P, "Experimental neurological syndromes and the new drug therapies in psychiatry" 1 : 92-102, 1960

52 Olfson M, "Essential roles for psychiatry in the era of managed care" 54 : 206-208, 1997

53 Carlsson A, "Effect of chlorpromazine or haloperidol on formation of 3methoxytramine and normetanephrine in mouse brain" 20 : 140-144, 1963

54 Hamon J, "Effect of R. P. 4560 on maniacal agitation" 110 : 331-335, 1952

55 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders" American Psychiatric Publishing 2013

56 Hasse HJ, "Definition and mode of action of the psychomotor Parkinson syndrome therapeutically induced by serpasil and largactil" 131 : 201-214, 1956

57 Baumeister AA, "Continuity and discontinuity in the historical development of modern psychopharmacology" 14 : 199-209, 2005

58 Lehmann HE, "Concepts, rationale and research" J & A Churchill Ltd 21-30, 1959

59 Leucht S, "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia : a multiple-treatments meta-analysis" 382 : 951-962, 2013

60 International Schizophrenia Consortium, "Common polygenic variation contributes to risk of schizophrenia and bipolar disorder" 460 : 748-752, 2009

61 Baldessarini RJ, "Commentary : the current state of psychopharmacology and psychiatry" 4 : 5-8, 2011

62 Anderman B, "Clozapine-induced agranulocytosis : a situation report up to August 1976" 11 : 199-201, 1977

63 Kane JM, "Clozapine for the treatment-resistant schizophrenics" 24 : 62-67, 1988

64 Nucifora FC Jr, "Clozapine as a model for antipsychotic development" 14 : 750-761, 2017

65 Meltzer HY, "Clozapine : new research on efficacy and mechanism of action" 238 : 332-339, 1989

66 Depp C, "Clinical trials : bridging the gap between efficacy and effectiveness" 19 : 531-539, 2007

67 Bahk WM, "Clinical Neuropsychopharmacology" Sigma Press 3-11, 2014

68 Meltzer HY, "Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and Serotonin2pKi values" 251 : 238-246, 1989

69 Casey AB, "Classics in Chemical Neuroscience : aripiprazole" 8 : 1135-1146, 2017

70 Lilienfeld SO, "Clashing diagnostic approaches : DSMICD versus RDoC" 12 : 435-463, 2016

71 Lehmanne HE, "Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states" 71 : 227-237, 1954

72 Delay J, "Chlorpromazine and neuroleptic treatments in psychiatry" 17 : 19-24, 1956

73 Forray C, "Challenges and opportunities for the development of new antipsychotic drugs" 143 : 10-24, 2017

74 Delay J, "Cas de psychoses traitées par la cure prolongée et continue de 4560 RP. CR 50e Congrès des aliénistes et neurol" 38 : 503-513, 1952

75 Citrome L, "Cariprazine for the treatment of schizophrenia : a review of this dopamine D3-preferring D3/D2 receptor partial agonist" 10 : 109-119, 2016

76 McEvoy J, "Brexpiprazole for the treatment of schizophrenia : a review of this novel serotonin-dopamine activity modulator" 9 : 177-186, 2016

77 Lehmann HE, "Before they called it psychopharmacology" 8 : 291-303, 1993

78 Nikiforuk A, "Assessment of cognitive functions in animal models of schizophrenia" 70 : 639-649, 2018

79 Preissmann D, "Anxiety modulates cognitive deficits in a perinatal glutathione deficit animal model of schizophrenia" 1648 : 459-468, 2016

80 Tandon R, "Antipsychotic treatment of schizophrenia : two steps for ward, one step back" 9 : 263-264, 2007

81 Leucht S, "Antipsychotic drugs versus placebo for relapse prevention in schizophrenia : a systematic review and meta-analysis" 379 : 2063-2071, 2012

82 Remington G, "Antipsychotic dosing : found in translation" 39 : 223-231, 2014

83 Carpenter WT Jr, "Another view of the history of antipsychotic drug discovery and development" 17 : 1168-1173, 2012

84 Moncrieff J, "An investigation into the precedents of modern drug treatment in psychiatry" 10 : 475-490, 1999

85 Amsler HA, "Agranulocytosis in patients treated with Clozaril. A study of the Finnish epidemic" 56 : 241-248, 1977

86 Pisciotta AV, "Agranulocytosis following administration of phenothiazine derivatives" 25 : 210-223, 1958

87 Delay J, "A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses" 118 : 145-152, 1960

88 Kikuchi T, "7-(4-[4-(2, 3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinone(OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity" 274 : 329-336, 1995

89 Bennett D, "150 years of British Psychiatry, 1841-1991" Gaskell/Royal College of Psychiatrists 321-332, 1991

90 Rebec GV, ""Classical"and"atypical"antipsychotic drugs : differential antagonism of amphetamine-and apomorphine-induced alterations of spontaneous neuronal activity in the neostriatum and nucleus accumbens" 11 : 529-538, 1979